JP2011121957A5 - - Google Patents

Download PDF

Info

Publication number
JP2011121957A5
JP2011121957A5 JP2011000273A JP2011000273A JP2011121957A5 JP 2011121957 A5 JP2011121957 A5 JP 2011121957A5 JP 2011000273 A JP2011000273 A JP 2011000273A JP 2011000273 A JP2011000273 A JP 2011000273A JP 2011121957 A5 JP2011121957 A5 JP 2011121957A5
Authority
JP
Japan
Prior art keywords
flt4
antibody
fragment
pharmaceutical composition
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011000273A
Other languages
English (en)
Japanese (ja)
Other versions
JP5784310B2 (ja
JP2011121957A (ja
Filing date
Publication date
Priority claimed from US09/169,079 external-priority patent/US6824777B1/en
Application filed filed Critical
Publication of JP2011121957A publication Critical patent/JP2011121957A/ja
Publication of JP2011121957A5 publication Critical patent/JP2011121957A5/ja
Application granted granted Critical
Publication of JP5784310B2 publication Critical patent/JP5784310B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2011000273A 1998-10-09 2011-01-04 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３） Expired - Lifetime JP5784310B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/169,079 1998-10-09
US09/169,079 US6824777B1 (en) 1992-10-09 1998-10-09 Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2000575533A Division JP4841724B2 (ja) 1998-10-09 1999-10-08 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2013097900A Division JP2013209382A (ja) 1998-10-09 2013-05-07 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
JP2015077656A Division JP2015157829A (ja) 1998-10-09 2015-04-06 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）

Publications (3)

Publication Number Publication Date
JP2011121957A JP2011121957A (ja) 2011-06-23
JP2011121957A5 true JP2011121957A5 (enExample) 2012-09-27
JP5784310B2 JP5784310B2 (ja) 2015-09-24

Family

ID=22614189

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2000575533A Expired - Fee Related JP4841724B2 (ja) 1998-10-09 1999-10-08 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
JP2011000273A Expired - Lifetime JP5784310B2 (ja) 1998-10-09 2011-01-04 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
JP2011178553A Expired - Fee Related JP5642637B2 (ja) 1998-10-09 2011-08-17 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
JP2013097900A Pending JP2013209382A (ja) 1998-10-09 2013-05-07 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
JP2015077656A Pending JP2015157829A (ja) 1998-10-09 2015-04-06 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2000575533A Expired - Fee Related JP4841724B2 (ja) 1998-10-09 1999-10-08 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011178553A Expired - Fee Related JP5642637B2 (ja) 1998-10-09 2011-08-17 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
JP2013097900A Pending JP2013209382A (ja) 1998-10-09 2013-05-07 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）
JP2015077656A Pending JP2015157829A (ja) 1998-10-09 2015-04-06 腫瘍イメージングおよび抗腫瘍治療の標的としてのＦｌｔ４（ＶＥＲＧ−３）

Country Status (13)

Country Link
US (4) US8444957B2 (enExample)
EP (1) EP1119371B1 (enExample)
JP (5) JP4841724B2 (enExample)
CN (1) CN100340291C (enExample)
AT (1) ATE489108T1 (enExample)
AU (2) AU774266B2 (enExample)
CA (1) CA2345276C (enExample)
DE (1) DE69942981D1 (enExample)
DK (1) DK1119371T3 (enExample)
ES (1) ES2357406T3 (enExample)
NO (1) NO20011759L (enExample)
NZ (2) NZ529063A (enExample)
WO (1) WO2000021560A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US7423125B2 (en) 1995-08-01 2008-09-09 Vegenics Limited Antibodies to VEGF-C
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
ATE489108T1 (de) * 1998-10-09 2010-12-15 Vegenics Ltd Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
US7223724B1 (en) 1999-02-08 2007-05-29 Human Genome Sciences, Inc. Use of vascular endothelial growth factor to treat photoreceptor cells
EP1553414A1 (en) * 1999-04-13 2005-07-13 Medarex, Inc. Methods for the diagnosis and treatment of metastatic prostate tumors
AU2001239884B2 (en) 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
US7273751B2 (en) 2000-08-04 2007-09-25 Human Genome Science, Inc. Vascular endothelial growth factor-2
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
DE60236646D1 (de) 2001-04-13 2010-07-22 Human Genome Sciences Inc Anti-VEGF-2 Antikörper
US7109165B2 (en) 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20040242851A1 (en) * 2001-06-26 2004-12-02 Zhenping Zhu Bispecific antibodies that bind to vegf receptors
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
AU2003207708A1 (en) * 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8003613B2 (en) 2003-11-17 2011-08-23 University Of Florida Research Foundation, Inc. Methods and compositions for inducing apoptosis
JP2007523649A (ja) 2004-02-10 2007-08-23 サーナ・セラピューティクス・インコーポレイテッド 多機能短鎖干渉核酸（多機能ｓｉＮＡ）を用い、ＲＮＡ干渉を介した遺伝子発現の阻害
WO2005087177A2 (en) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Chimeric anti-vegf-d antibodies and humanized anti-vegf-d antibodies and methods of using same
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
WO2007022287A2 (en) 2005-08-15 2007-02-22 Vegenics Limited Modified vegf and pdgf with improved angiogenic properties
US9201063B2 (en) 2006-11-16 2015-12-01 General Electric Company Sequential analysis of biological samples
US7629125B2 (en) 2006-11-16 2009-12-08 General Electric Company Sequential analysis of biological samples
US8305579B2 (en) 2006-11-16 2012-11-06 Thomas Pirrie Treynor Sequential analysis of biological samples
US9677125B2 (en) 2009-10-21 2017-06-13 General Electric Company Detection of plurality of targets in biological samples
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP2911681A1 (en) 2012-10-26 2015-09-02 Institut National de la Santé et de la Recherche Médicale (INSERM) Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis
MY199344A (en) 2013-02-18 2023-10-24 Vegenics Pty Ltd Ligand binding molecules and uses thereof
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
KR102131370B1 (ko) 2013-10-18 2020-07-08 삼성전자주식회사 Vegf-c에 특이적으로 결합하는 폴리펩타이드 및 그의 용도
CN114262683B (zh) * 2022-03-01 2022-06-17 中国科学院动物研究所 一种表达vegfr3 d2多肽的细菌制剂及其构建方法和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652639A (en) 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
EP0171407B1 (en) 1984-01-30 1993-11-18 Imperial Cancer Research Technology Limited Improvements relating to growth factors
JP2736255B2 (ja) 1987-03-11 1998-04-02 フアルマシア・エ・アツプジヨン・エツセ・ピー・アー イムノグロブリン結合体
EP0721983A1 (en) 1988-01-22 1996-07-17 ZymoGenetics, Inc. Methods of producing biologically active peptide dimers
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2011450C (en) 1989-03-07 2002-06-04 Tadatsugu Taniguchi Recombinant b-chain of the il-2 receptor
JPH04505260A (ja) 1989-05-22 1992-09-17 ザイモジェネティクス，インコーポレイティド ＰＤＧＦα―受容体
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
EP0584082B1 (en) 1991-01-31 2000-05-31 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5256766A (en) 1991-02-19 1993-10-26 The Regents Of The University Of California Recombinant thrombin receptor and related pharmaceuticals
WO1992014748A1 (en) 1991-02-22 1992-09-03 American Cyanamid Company Identification of a novel human receptor tyrosine kinase gene
US5231001A (en) 1991-03-14 1993-07-27 The United States Of America As Represented By The Department Of Health And Human Services Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5270458A (en) 1991-04-02 1993-12-14 The Trustees Of Princeton University Nucleic acids encoding fragments of hematopoietic stem cell receptor flk-2
US5185438A (en) 1991-04-02 1993-02-09 The Trustees Of Princeton University Nucleic acids encoding hencatoporetic stem cell receptor flk-2
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
JPH07506242A (ja) 1992-01-09 1995-07-13 ヘルシンキ　ユニバーシティ　ホルディング　リミテッド Ｔｉｅ，新規内皮細胞受容体チロシンキナーゼ
US6331302B1 (en) 1992-01-22 2001-12-18 Genentech, Inc. Protein tyrosine kinase agonist antibodies
CA2128722A1 (en) 1992-01-22 1993-08-05 William I. Wood Novel protein tyrosine kinases
US5635177A (en) 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
US5776755A (en) 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
DK1975181T3 (da) 1992-10-28 2011-06-06 Genentech Inc Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
EP0751992B1 (en) 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vascular endothelial growth factor 2
US6608182B1 (en) 1994-03-08 2003-08-19 Human Genome Sciences, Inc. Human vascular endothelial growth factor 2
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
ES2263152T3 (es) * 1994-06-09 2006-12-01 Licentia Oy Anticuerpo monoclonal contra el receptor flt4 tirosina quinasa y su uso en diagnostico y terapia.
US5763733A (en) 1994-10-13 1998-06-09 Enzon, Inc. Antigen-binding fusion proteins
WO1998033917A1 (en) 1994-11-14 1998-08-06 The Ludwig Institute For Cancer Research Vascular endothelial growth factor c (vegf-c) protein and gene, mutants thereof, and uses thereof
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
ES2202469T5 (es) 1995-09-08 2011-06-06 Genentech, Inc. Proteína relacionada con el vegf.
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
AU3968597A (en) * 1996-08-02 1998-02-25 Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors
CA2263890C (en) 1996-08-23 2013-05-14 Ludwig Institute For Cancer Research Recombinant vascular endothelial cell growth factor d (vegf-d)
KR100628697B1 (ko) 1997-12-24 2006-09-28 루드빅 인스티튜트 포 캔서 리서치 맥관 내피 성장인자 ｄ를 발현하는 발현 벡터와 셀라인,및 흑색종을 치료하는 방법
ATE489108T1 (de) * 1998-10-09 2010-12-15 Vegenics Ltd Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
KR101681886B1 (ko) 2015-04-06 2016-12-12 서울대학교산학협력단 지르코니아 결합능을 가지는 펩타이드

Similar Documents

Publication Publication Date Title
JP2012019790A5 (enExample)
Tschernia et al. Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy: NP Tschernia and JL Gulley
Kasprzak et al. Role of endoglin (CD105) in the progression of hepatocellular carcinoma and anti-angiogenic therapy
Roland et al. Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts
JP6858181B2 (ja) 免疫チェックポイントブロッカーを用いる治療の臨床アウトカムを予測するための診断マーカーとしてのｇｄｆ−１５
JP6865585B2 (ja) 成長分化因子１５（ｇｄｆ−１５）に対するモノクローナル抗体およびがん悪液質およびがんを処置するためのその使用
JP6925326B2 (ja) ヒト成長分化因子１５（ｇｄｆ−１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法
JP2021531254A (ja) 高親和性のアイソフォーム選択的ＴＧＦβ１阻害剤、およびその使用
JP2021503077A (ja) 細胞外小胞タンパク質、ならびに癌診断、療法に対する応答予測、および治療をするためのそれらの使用
AU2013302620B2 (en) Stem cell enhancing therapeutics
CN112703012A (zh) 治疗癌症的方法
JP2021515805A (ja) 抗ｃｄ４７抗体及び抗ｃｄ２０抗体を使用する抗がんレジメン
JP2002527404A5 (enExample)
RS59045B1 (sr) Monoklonalna antitela za faktor 15 rasta i diferencijacije (gdf-15)
CA2786479A1 (en) Methods for treating pancreatic cancer
JP2019505485A (ja) Ｃｄ４７及びｅｇｆｒの二重標的化による癌治療
JP2013531655A5 (enExample)
JP7763850B2 (ja) ＰＤＧＦＲα阻害剤でがんを治療する方法
JP2017538439A5 (enExample)
WO2014068300A1 (en) Anti-s100a4 antibody molecules and their uses
Li et al. Activating CD137 signaling promotes sprouting angiogenesis via increased VEGFA secretion and the VEGFR2/Akt/eNOS pathway
RU2014145633A (ru) Композиции и способы для диагностики и лечения опухолей
Stacher et al. The VEGF-system in primary pulmonary angiosarcomas and haemangioendotheliomas: new potential therapeutic targets?
Sullivan et al. r84, a novel therapeutic antibody against mouse and human VEGF with potent anti-tumor activity and limited toxicity induction
JP2021510738A (ja) ４−１ｂｂと組み合わせたキメラ抗原受容体免疫治療製品の投与方法